You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company said it intends to use the technology to develop infectious disease diagnostics, with an initial focus on SARS-CoV-2.
Emerging technologies included biosensors, host response tests using different types of biomarkers, and new ways to make and develop antigen, antibody, and PCR tests.
Called the "Ccheck Prostate Cancer Confirmation" test, Anixa's assay integrates flow cytometry and machine learning to identify evidence of cancer in a person's bloodstream.
The firm aims to have its test on the European clinical market by early next year, followed by a launch in the US.
Researchers implemented qPCR on TaqMan Array Cards to find six pathogens are responsible for up to 90 percent of childhood diarrhea at seven sites in Africa and Asia.